Literature DB >> 28416240

Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience.

Mariangela Allocca1, Cristiana Bonifacio2, Gionata Fiorino1, Antonino Spinelli3, Federica Furfaro1, Luca Balzarini2, Stefanos Bonovas1, Silvio Danese4.   

Abstract

BACKGROUND: Stenosis is the most common complication of Crohn's disease (CD). Long-term outcome of patients receiving tumour necrosis factor (TNF) antagonists for such disease complication is poorly understood.
METHODS: 51 CD patients (from July 2006 to November 2015) who had a diagnosis of small bowel or colonic stenosis, diagnosed by colonoscopy and/or MRI enterography, and were treated with TNF antagonists (adalimumab or infliximab) were enrolled. The primary outcome was to assess the rate of success of TNF antagonists on avoiding abdominal surgery for stricturing CD patients.
RESULTS: 20 patients (39.2%) underwent surgery during the follow-up period. The overall incidence of abdominal surgery was 1.8 per 100 person-months at risk, while the median time to surgery was 37.9 months. The univariable and multivariable Cox's proportional hazards analysis of baseline parameters indicated that disease location (colonic vs ileal, HR: 28.2, 95% CI: 2.45-324, p=0.007; ileocolonic vs ileal, HR: 3.38, 95% CI: 1.09-10.5, p=0.035), prestenotic dilatation (per 1-mm increase, HR: 1.08, 95% CI: 1.01-1.15, p=0.022) and the existence of non-perianal fistula (HR: 9.77, 95% CI: 2.99-31.9, p<0.001) are independent risk factors for abdominal surgery.
CONCLUSIONS: In stricturing CD, anti-TNFs are effective in up to about two-thirds of the patients.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Adalimumab; Anti-TNF; Crohn’s disease; Fistulae; Infliximab; Stenosis

Mesh:

Substances:

Year:  2017        PMID: 28416240     DOI: 10.1016/j.dld.2017.03.012

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  10 in total

1.  Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.

Authors:  Iago Rodríguez-Lago; Javier Del Hoyo; Alexandre Pérez-Girbés; Alejandro Garrido-Marín; María José Casanova; María Chaparro; Agnès Fernández-Clotet; Jesús Castro-Poceiro; María José García; Sara Sánchez; Rocío Ferreiro-Iglesias; Iria Bastón; Marta Piqueras; Lola Esteba I Bech de Careda; Raquel Mena; Cristina Suárez; Joaquín Poza Cordón; Alicia López-García; Lucía Márquez; Maite Arroyo; Erika Alfambra; Mónica Sierra; Noelia Cano; Pedro Delgado-Guillena; Víctor Morales-Alvarado; Juan Carlos Aparicio; Iván Guerra; Carolina Aulló; Olga Merino; Laura Arranz; María Araceli Hidalgo; Jordina Llaó; Rocío Plaza; Gema Molina; Paola Torres; Pablo Pérez-Galindo; María Giselle Romero; Claudia Herrera-deGuise; Edisa Armesto; Francisco Mesonero; Santiago Frago-Larramona; José Manuel Benítez; Marta Calvo; María Del Carmen López Martín; Ainara Elorza; Alejandro Larena; Elena Peña; María Del Carmen Rodríguez-Grau; Jaime de Miguel-Criado; Belén Botella; José Antonio Olmos; Laura López; Urko Aguirre; Javier P Gisbert
Journal:  United European Gastroenterol J       Date:  2020-07-28       Impact factor: 4.623

Review 2.  Medical, Endoscopic and Surgical Management of Stricturing Crohn's Disease: Current Clinical Practice.

Authors:  Fotios S Fousekis; Ioannis V Mitselos; Kostas Tepelenis; George Pappas-Gogos; Konstantinos H Katsanos; Georgios D Lianos; Francesco Frattini; Konstantinos Vlachos; Dimitrios K Christodoulou
Journal:  J Clin Med       Date:  2022-04-23       Impact factor: 4.964

3.  Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy.

Authors:  Alessandro Sartini; Eleonora Scaioli; Elisa Liverani; Matteo Bellanova; Luigi Ricciardiello; Franco Bazzoli; Andrea Belluzzi
Journal:  Dig Dis Sci       Date:  2018-10-17       Impact factor: 3.199

Review 4.  Natural history, diagnosis and treatment approach to fibrostenosing Crohn's disease.

Authors:  Sara El Ouali; Benjamin Click; Stefan D Holubar; Florian Rieder
Journal:  United European Gastroenterol J       Date:  2020-01-14       Impact factor: 4.623

5.  Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn's disease.

Authors:  Sudheer K Vuyyuru; Bhaskar Kante; Peeyush Kumar; Pabitra Sahu; Saurabh Kedia; Mukesh Kumar Ranjan; Raju Sharma; Rajesh Panwar; Govind Makharia; Vineet Ahuja
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

Review 6.  Revisiting fibrosis in inflammatory bowel disease: the gut thickens.

Authors:  Silvia D'Alessio; Federica Ungaro; Daniele Noviello; Sara Lovisa; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-12-07       Impact factor: 46.802

Review 7.  Therapeutic Targeting of Intestinal Fibrosis in Crohn's Disease.

Authors:  Giovanni Santacroce; Marco Vincenzo Lenti; Antonio Di Sabatino
Journal:  Cells       Date:  2022-01-26       Impact factor: 6.600

Review 8.  Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy.

Authors:  Yifei Wang; Bin Huang; Tao Jin; Dickson Kofi Wiredu Ocansey; Jiajia Jiang; Fei Mao
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

Review 9.  Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges.

Authors:  Joseph Sleiman; Sara El Ouali; Taha Qazi; Benjamin Cohen; Scott R Steele; Mark E Baker; Florian Rieder
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-12-28       Impact factor: 3.869

10.  Astragalus membranaceus (Fisch.) Bunge repairs intestinal mucosal injury induced by LPS in mice.

Authors:  Yizhe Cui; Qiuju Wang; Rui Sun; Li Guo; Mengzhu Wang; Junfeng Jia; Chuang Xu; Rui Wu
Journal:  BMC Complement Altern Med       Date:  2018-08-03       Impact factor: 3.659

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.